Mechanism of Action of Cantharidin
Cantharidin is a blistering agent that triggers acantholysis—the breakdown of connections between epidermal cells—by inducing the release of serine proteases that disrupt desmosome plaques. 1, 2
Primary Mechanism: Acantholysis
The drug works by causing separation of keratinocytes in the epidermis through destruction of the intercellular bridges (desmosomes). This acantholytic effect creates an intraepidermal blister at the dermal-epidermal junction, which is why the injury remains superficial and reduces scarring risk 1. The blistering typically develops within 24 hours of application, though the application itself is painless 1.
Underlying Biochemical Action: Protein Phosphatase Inhibition
At the molecular level, cantharidin functions as a potent inhibitor of serine/threonine protein phosphatases (PP), particularly protein phosphatase type 1 (PP1) and type 2A (PP2A) 3, 4, 5. This inhibition:
- Increases the phosphorylation state of cellular regulatory proteins 4, 5
- Disrupts normal cell cycle progression, causing mitotic arrest at metaphase 3
- Creates aberrant mitotic spindles and lagging chromosomes 3
- Eventually triggers apoptosis in affected cells 3
The IC50 for phosphatase inhibition is remarkably low (0.38 μM for PP5), demonstrating high potency 6. This phosphatase inhibition explains both its therapeutic vesicant effects and its systemic toxicity when taken internally 1, 7.
Clinical Implications
The superficial nature of the acantholytic injury is therapeutically advantageous—it destroys the wart or lesion tissue without extending deep enough to cause significant scarring 1. However, the same phosphatase inhibition mechanism makes cantharidin highly toxic when absorbed systemically, which is why it must only be used topically and with careful application technique 1.
The drug is available in concentrations of 0.7% (for molluscum and common warts) or in combination formulations with salicylic acid and podophyllotoxin for more resistant plantar warts 2.